Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Tudor Investment Corp ET AL opened a new stake in Supernus Pharmaceuticals (NASDAQ:SUPN), buying 30,015 shares valued at approximately $1.43 million, about 0.05% of the company.
• Insiders sold heavily last quarter — CEO Jack Khattar sold 35,000 shares and VP Padmanabh Bhatt sold 50,000 shares, with insiders disposing of a total of 120,881 shares worth roughly $6.14 million, leaving insiders with 8.80% ownership.
• Analyst coverage is mixed (four Buys, one Hold, two Sells), giving a MarketBeat consensus rating of “Hold” and a consensus price target of $62.17.

Tudor Investment Corp ET AL bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,015 shares of the specialty pharmaceutical company's stock, valued at approximately $1,434,000. Tudor Investment Corp ET AL owned about 0.05% of Supernus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of SUPN. Jefferies Financial Group Inc. grew its position in shares of Supernus Pharmaceuticals by 62.0% during the 3rd quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company's stock valued at $4,118,000 after buying an additional 32,979 shares during the last quarter. Ruffer LLP bought a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at about $2,647,000. Teacher Retirement System of Texas grew its position in shares of Supernus Pharmaceuticals by 648.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 112,638 shares of the specialty pharmaceutical company's stock valued at $5,383,000 after buying an additional 97,597 shares during the last quarter. VELA Investment Management LLC bought a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at about $1,924,000. Finally, AdvisorShares Investments LLC bought a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at about $742,000.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Sunday, March 8th. Stifel Nicolaus boosted their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a "hold" rating in a research report on Friday, December 19th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Zacks Research downgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Thursday, January 29th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 35,000 shares of the company's stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the transaction, the chief executive officer owned 958,100 shares in the company, valued at approximately $48,259,497. This represents a 3.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Padmanabh P. Bhatt sold 50,000 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the completion of the transaction, the vice president owned 17,044 shares of the company's stock, valued at approximately $856,972.32. This trade represents a 74.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 120,881 shares of company stock worth $6,139,356 in the last quarter. 8.80% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $50.68 on Monday. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $59.68. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -74.53, a price-to-earnings-growth ratio of 1.57 and a beta of 0.73. The company has a 50-day moving average price of $51.34 and a two-hundred day moving average price of $49.75.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.